IOVA Iovance Corp Company Short-Term Debt

Iovance Biotherapeutics, Inc. - graphic logo of issuer IOVA

Iovance Biotherapeutics (IOVA) is a pioneer in solid tumor therapy with exclusive FDA approval for Amtagvi, possessing assets protected by US law and free from external pressure. This price chart illustrates the asset's dynamics, where the metric stands at 0.00. The company minimizes risks by developing cutting-edge T-cell solutions to combat various forms of cancer, significantly expanding its market potential.

IOVA iovance.com Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Iovance Corp (IOVA)

- current quotes and average value forecast:
Price Chart Iovance Biotherapeutics, Inc.|IOVA - Average Forecast Price
- market capitalization data:
Market Value Iovance Biotherapeutics, Inc.|IOVA - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Iovance Biotherapeutics|IOVA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio iovance.com|IOVA - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Iovance Biotherapeutics|IOVA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Iovance Biotherapeutics|IOVA - Aggregate Debt Obligations|Debts to Book Capitalization Iovance Biotherapeutics, Inc.|IOVA - Long-Term Debt Volume|Company Short-Term Debt Iovance Biotherapeutics|Quick Liquidity iovance.com
- earnings and multiples data:
IOVA - Net Income
General company analysis:Iovance Biotherapeutics, Inc. (IOVA)
Flagship merchandise of iovance.com

Iovance Biotherapeutics (IOVA) maintains its status as a leader in TIL therapy, and FDA approval makes the company an attractive hub for top immunologists. An analysis of short-term borrowings under one year allows for tracking the dynamics of short-term liabilities, which are typically obscured in quarterly reports. This metric aggregates all loans maturing within twelve months, measuring the real-time pressure on liquidity. Sharp fluctuations in this indicator signal refinancing risks for operating expenses. The stability of this figure confirms the financial resilience of the company's scientific business model.

Competitors of Iovance Biotherapeutics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IMTX|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)